Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
283people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
evogliptin add-on to DAPA/MET therapy
placebo
Probably lowered HbA1c reduction at week 24−0.65
Probably lowered HbA1c reduction at week 52−0.55
randomisedThe trial randomly assignedassigned by chance
evogliptin
the rest
Probably raised homeostatic model assessment of β-cell function+9.04
randomisedthe abstract, start to end
… 52 (least square [LS] mean difference, -0.65% and -0.55%; 95% confidence interval [CI], …
… of β-cell function (LS mean difference, 9.04; 95% CI, 1.86 to 16.21; …
← favours treatmentfavours comparator →
could be chanceHbA1c reduction at week 24evogliptin add-on to DAPA/MET therapy vs placebo
−0.65−0.79 to −0.51
HbA1c reduction at week 52evogliptin add-on to DAPA/MET therapy vs placebo
−0.55−0.71 to −0.39
Glycemic control
−0.55−0.79 to −0.51
Homeostatic model assessment of β-cell functionevogliptin
9.041.86–16.2
MetforminSGLT2 inhibitorsDPP-4 inhibitorsGlycemic control
DPP-4 inhibitors × glycemic controlhelps?replicated
unlikelylikely
0.820.82 without it
SGLT2 inhibitors × glycemic controlhelps?replicated
unlikelylikely
0.920.92 without it
Metformin × glycemic controlhelps?replicated
unlikelylikely
0.840.84 without it
← favours treatmentfavours comparator →
1 / 6